Siemens Healthineers to Close Fast Track Diagnostics Unit

Siemens Healthineers has announced the closure of its Fast Track Diagnostics (FTD) unit, a small collection of polymerase chain reaction (PCR) testing products that is part of the Diagnostics business.

In December 2017 Siemens Healthineers announced the acquisition of Luxembourg-based Fast Track Diagnostics, underscoring its commitment to molecular diagnostics. FTD’s business, which is sold primarily in Europe, has declined significantly since the peak of the COVID-19 pandemic. Fast Track Diagnostics is a small player in molecular diagnostics and represents a very small portion of the total revenues of Siemens Healthineers’ Diagnostics business.

Approximately 90 employees, mainly in Luxembourg, will be affected. Discussions with local employee representatives are underway and local labour regulations and policies will be followed in accordance with standard company practice. Siemens Healthineers intends to close FTD business by September 2024.

Siemens Healthineers offers in vitro diagnostic test solutions for nearly every clinical environment. Its central laboratory analyzers are used in research laboratories, clinical laboratories of local community hospitals, independent specialty laboratories, and in the largest reference labs in the world. Point-of-care testing solutions support care everywhere from remote pop-up health clinics to community physician offices, and outpatient care facilities to patients’ bedsides in hospital units. Siemens Healthineers has differentiated its in vitro diagnostic test offerings with flexible, scalable, and integrated automation capabilities that increase control over laboratory testing and operational workflows.

To view the source version, please click HERE.

en_GBEnglish (UK)